GALVANIZE Study of SZC Therapy for Hyperkalemia

By Charlotte Robinson, Pooja Desai, PhD - Last Updated: May 29, 2024

Pooja Desai, PhD, of AstraZeneca discussed the GALVANIZE study results being presented at the 2024 National Kidney Foundation Spring Clinical Meetings. The study examined short-term versus long-term results of SZC therapy on hyperkalemia-related hospitalization.

Post Tags:hyperkalemia Nephrology Nephrology Videos

Cesia Portillo on the AMKD Roadmap

Cesia Portillo, MPHNKF Spring Clinical Meetings 2024 | June 4, 2024

Cesia Portillo discussed her poster on creating a roadmap for APOL1-mediated kidney disease (AMKD).

Suzanne Watnick, Shaul G. Massry Distinguished Lecturer

Suzanne Watnick, MDNKF Spring Clinical Meetings 2024 | June 3, 2024

Suzanne Watnick shared thoughts on the Shaul G. Massry lectureship, COVID-19, kidney transplantation, and policy issues.

Inaugural Neph Madness Tournament Winners

Yasemin Balin, MDNKF Spring Clinical Meetings 2024 | June 3, 2024

A. Ersin Yassa and Yasemin Balin were the winners of the inaugural Neph Madness tournament.

Insights from David M. Hume Award Winner Martin Pollak

Joel M. Topf, MD, FACPNKF Spring Clinical Meetings 2024 | May 31, 2024

Martin Pollak reflected on winning the David M. Hume Memorial Award and on breakthroughs in glomerular diseases.

NKF President Sylvia Rosas on Highlights in Kidney Care

Sylvia Rosas, MD, MSCENKF Spring Clinical Meetings 2024 | May 31, 2024

Sylvia Rosas shared highlights from her term as president of the National Kidney Foundation.

GALVANIZE Study of SZC Therapy for Hyperkalemia

Related Posts